Asia-Pacific Vaccine Market - 2024-2031
Asia-Pacific Vaccine Market reached US$ 12.33 billion in 2023 and is expected to reach US$ 17.82 billion by 2031, growing with a CAGR of 6.10% during the forecast period 2026-2031.
The Asia-Pacific Vaccine Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Asia-Pacific Vaccine Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Composition
Both primary and secondary data sources have been used in the global Asia-Pacific Vaccine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Asia-Pacific Vaccine Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Asia-Pacific Vaccine Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Composition
- Combination Vaccines*
- Mono Vaccines
- CD30 Antibodies *
- Live-Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Others
- Pediatrics*
- Adults
- Injectables*
- Oral
- Others
- Pneumococcal Disease*
- Pneumococcal Disease
- Measles
- Mumps & Varicella (Chickenpox)
- DPT (Diphtheria, Pertussis, Tetanus)
- Hepatitis
- Influenza
- Typhoid
- Meningococcal Disease
- Rabies
- Japanese Encephalitis
- Yellow Fever
- Others
- Hospitals & Specialty Clinics*
- Vaccination Centers
- Others
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Asia-Pacific Vaccine Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Composition
3.2. Snippet by Type
3.3. Snippet by Age Group
3.4. Snippet by Route of Administration
3.5. Snippet by Application
3.6. Snippet by End-User
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Infectious Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. BY COMPOSITION
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Composition
6.1.2. Market Attractiveness Index, By Composition
6.2. Combination Vaccines*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Mono Vaccines
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. CD30 Antibodies *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Live-Attenuated Vaccines
7.4. Inactivated Vaccines
7.5. Toxoid Vaccines
7.6. Others
8. BY AGE GROUP
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Pediatrics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
9. BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Injectables*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oral
9.4. Others
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Pneumococcal Disease*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pneumococcal Disease
10.4. Measles
10.5. Mumps & Varicella (Chickenpox)
10.6. DPT (Diphtheria, Pertussis, Tetanus)
10.7. Hepatitis
10.8. Influenza
10.9. Typhoid
10.10. Meningococcal Disease
10.11. Rabies
10.12. Japanese Encephalitis
10.13. Yellow Fever
10.14. Others
11. BY END-USER
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals & Specialty Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Vaccination Centers
11.4. Others
12. ASIA-PACIFIC
12.1. Introduction
12.2. Key Region-Specific Dynamics
12.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
12.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.9.1. China
12.9.2. India
12.9.3. Japan
12.9.4. South Korea
12.9.5. Australia
12.9.6. Indonesia
12.9.7. Malaysia
12.9.8. Singapore
12.9.9. Thailand
12.9.10. Rest of Asia-Pacific
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. COMPANY PROFILES
14.1. Serum Institute of India Pvt. Ltd. *
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Bharat Biotech
14.3. CSL
14.4. GSK plc
14.5. Pfizer Inc.
14.6. Biological E Limited.
14.7. Takeda Pharmaceutical Company Limited.
14.8. Sanofi
14.9. Merck & Co., Inc.
14.10. Abbott (*LIST NOT EXHAUSTIVE)
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. DEFINITION AND OVERVIEW
3. EXECUTIVE SUMMARY
3.1. Snippet by Composition
3.2. Snippet by Type
3.3. Snippet by Age Group
3.4. Snippet by Route of Administration
3.5. Snippet by Application
3.6. Snippet by End-User
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Infectious Diseases
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Stringent Regulatory Requirements
4.1.3. Opportunity
4.1.4. Impact Analysis
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. BY COMPOSITION
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Composition
6.1.2. Market Attractiveness Index, By Composition
6.2. Combination Vaccines*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Mono Vaccines
7. BY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. CD30 Antibodies *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Live-Attenuated Vaccines
7.4. Inactivated Vaccines
7.5. Toxoid Vaccines
7.6. Others
8. BY AGE GROUP
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Pediatrics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
9. BY ROUTE OF ADMINISTRATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Injectables*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oral
9.4. Others
10. BY APPLICATION
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Pneumococcal Disease*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Pneumococcal Disease
10.4. Measles
10.5. Mumps & Varicella (Chickenpox)
10.6. DPT (Diphtheria, Pertussis, Tetanus)
10.7. Hepatitis
10.8. Influenza
10.9. Typhoid
10.10. Meningococcal Disease
10.11. Rabies
10.12. Japanese Encephalitis
10.13. Yellow Fever
10.14. Others
11. BY END-USER
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11.1.2. Market Attractiveness Index, By End-User
11.2. Hospitals & Specialty Clinics*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Vaccination Centers
11.4. Others
12. ASIA-PACIFIC
12.1. Introduction
12.2. Key Region-Specific Dynamics
12.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Composition
12.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
12.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
12.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
12.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
12.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.9.1. China
12.9.2. India
12.9.3. Japan
12.9.4. South Korea
12.9.5. Australia
12.9.6. Indonesia
12.9.7. Malaysia
12.9.8. Singapore
12.9.9. Thailand
12.9.10. Rest of Asia-Pacific
13. COMPETITIVE LANDSCAPE
13.1. Competitive Scenario
13.2. Market Positioning/Share Analysis
13.3. Mergers and Acquisitions Analysis
14. COMPANY PROFILES
14.1. Serum Institute of India Pvt. Ltd. *
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Bharat Biotech
14.3. CSL
14.4. GSK plc
14.5. Pfizer Inc.
14.6. Biological E Limited.
14.7. Takeda Pharmaceutical Company Limited.
14.8. Sanofi
14.9. Merck & Co., Inc.
14.10. Abbott (*LIST NOT EXHAUSTIVE)
15. APPENDIX
15.1. About Us and Services
15.2. Contact Us
